Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.

Drugs and Therapeutics (D & T) Committee Meeting Results for: March 20, 2013

Drug Name Review Type Committee Recommendation Prior Approval Status � Final Determination
Quillivant XR New Drug Initial Review Require Prior Approval Prior Approval Required
Xeljanz New Drug Initial Review Require Prior Approval Prior Approval Required
Aubagio New Drug Initial Review Require Prior Approval Prior Approval Required
Eliquis New Drug Initial Review Require Prior Approval Prior Approval Required
Sklice New Drug Initial Review Require Prior Approval Prior Approval Required
Gattex New Drug Initial Review Require Prior Approval Prior Approval Required
Oxtellar XR New Drug Initial Review Require Prior Approval Prior Approval Required
Tudzorza Pressair New Drug Initial Review Require Prior Approval Prior Approval Required
Natroba New Drug Appeal Require Prior Approval Prior Approval Required
Brilinta PDL Appeal Require Prior Approval Prior Approval Required
Latuda PDL Appeal Remove Prior Approval Requirement Prior Approval Requirement Removed